Follow
Cline Scientific AB
Spotlight (Sweden)
Cline Scientific develops cancer diagnostics and regenerative medicine treatments. The company is working with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase. Cline operates out of Gothenburg, Sweden and was founded in 2012 from a long term research project in surface nanotechnology.
Sector:
HEALTH CARE
Current instruments
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
CLINE B
SE0006758231
Spotlight
Sweden (SE)
Details of share in Cline Scientific AB with ticker CLINE B
Status
Active
Order book id
412T
Amount of instruments
8 441 112
Par value
0.1000
Market cap
24 300 000.00 SEK
Currency
SEK
First trading date
30 Mar 2015
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
6.00 SEK
34.8M SEK
26 Jan - 23 Feb 2015
IPO in Cline Scientific AB
Market
Spotlight
Subscription period
26 Jan - 23 Feb 2015
Subscription price
6.00 SEK
Price per share
6.00 SEK
Target to raise
10 200 000 SEK
Types
Share issue
Pre-money valuation
34 800 000 SEK
Subscription block size
Minimum subscription
1 000
Record date
Offer status
Closed
Listing status
Listed
First trading date
30 Mar 2015
Issue terms
Open to the public.
Comments for offer & related information
Cline Scientific begins trading on Aktietorget on March 30, 2015.
Type
Price
Pre-money valuation
Time
Files
New issue
6.50 SEK
48.7M SEK
13 Mar - 28 Mar 2018
Share issue in Cline Scientific AB
Market
Spotlight
Subscription period
13 Mar - 28 Mar 2018
Subscription price
6.50 SEK
Price per share
6.50 SEK
Target to raise
8 100 000 SEK
Types
Share issue
Pre-money valuation
48 700 000 SEK
Subscription block size
Minimum subscription
Record date
07 Mar 2018
Offer status
Closed
Listing status
Listed
Issue terms
Rights issue. Pre-emption 1:6. Each (1) existing share receives one (1) subscription right. Six (6) subscription rights are required to subscribe for one (1) new share.
Comments for offer & related information
Type
Price
Pre-money valuation
Time
Files
New issue
2.50 SEK
21M SEK
16 Mar - 02 Apr 2020
Share issue in Cline Scientific AB has been cancelled
Market
Spotlight
Subscription period
16 Mar - 02 Apr 2020
Subscription price
2.50 SEK
Price per share
2.50 SEK
Target to raise
7 000 000 SEK
Types
Share issue
Pre-money valuation
21 000 000 SEK
Subscription block size
Minimum subscription
Record date
10 Mar 2020
Offer status
Cancelled
Listing status
Listed
Issue terms
For each (1) existing Class A share, one (1) Class A common stock is obtained, and for each existing Class B share one (1) Class Three common stock is obtained. Three (3) Class Rights are required to subscribe for one (1) new Unit in Repective series. Each Unit consists of one (1) share and one (1) subscription option.
Comments for offer & related information
One (1) warrant entitle the holder to convert during the period 22 March - 8 April 2021 to one (1) share in each series where the conversion price is set at 80 percent of the weighted average trading price of the company's B share on Spotlight Stock Market during period March 1 - March 12, 2021.
Type
Price
Pre-money valuation
Time
Files
New issue
2.50 SEK
21M SEK
11 May - 28 May 2020
Share issue in Cline Scientific AB
Market
Spotlight
Subscription period
11 May - 28 May 2020
Subscription price
2.50 SEK
Price per share
2.50 SEK
Target to raise
7 000 000 SEK
Types
Share issue
Pre-money valuation
21 000 000 SEK
Subscription block size
Minimum subscription
Record date
06 May 2020
Offer status
Closed
Listing status
Listed
Issue terms
Preference right 1:3. For each (1) existing Class A share, one (1) Class A common stock is obtained, and for each existing Class B share one (1) Class Three (3) common stock is obtained. Three (3) Class Rights are required to subscribe for one (1) new Unit in respective series. Each Unit consists of one (1) share and one (1) subscription option.
Comments for offer & related information
The company issues a maximum of 2 813 703 units. The rights issue of SEK 7 million can be increased by SEK 3 million. One (1) warrants entitle the holder to convert during the period 2 March - 12 March 2021 into one (1) share in each series where the conversion price is set at 80 percent of the weighted average trading price of the company's B share on Spotlight Stock Market during periods February 8 - February 19, 2021.
Type
Ticker
ISIN
Market
OPTION
CLINE TO1 B
SE0013914512
Spotlight
Sweden (SE)
Details of option in Cline Scientific AB with ticker CLINE TO1 B
Status
Inactive
Order book id
Amount of instruments
Market cap
Currency
SEK
First trading date
Terms
One (1) warrant entitle the holder to convert during the period 2 March - 12 March 2021 into one (1) share in each series where the conversion price is set at 80 percent of the weighted average trading price of the company's B share on Spotlight Stock Market during periods February 8 - February 19, 2021.
Type
Price
Pre-money valuation
Time
Files
Exercise
02 Mar - 12 Mar 2021
Option exercise terms for CLINE TO1 B
Market
Spotlight
Exercise period(s)
02 Mar - 12 Mar 2021
Exercise price
Status
Upcoming
Issue terms
One (1) warrant entitle the holder to convert during the period 2 March - 12 March 2021 into one (1) share in each series where the conversion price is set at 80 percent of the weighted average trading price of the company's B share on Spotlight Stock Market during periods February 8 - February 19, 2021.
People
Patrik Sundh
CEO
Torleif Möllerström
Chairman of the board
Christopher Steele
Board member
Niklas Holmquist
Board member
Patrik Sundh
Board member
Company Details
Sector
HEALTH CARE

Address
Argongatan 2C
Zip code
431 53
City/district
Molndal
Country
Sweden (SE)
Registration number
556867-8238
LEI code
254900HHN7M1XTBL6885
First trade date
30 Mar 2015
Registration date
14 Oct 2011
Short name
Cline Scientific

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date